{"id":"W3087853974","doi":"10.1016/j.annonc.2020.08.454","title":"352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Pertuzumab; Hazard ratio; Trastuzumab; Internal medicine; Taxane; Breast cancer; Oncology; Clinical endpoint; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Placebo; Cancer; Clinical trial; Confidence interval; Pathology; Signal transduction","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001218751,0.00139424,0.001550741,0.0004838061,0.0003354054,0.00131589,0.0009113724,0.001076803,0.0044059],"category_scores_gemma":[0.0006118416,0.000566839,0.00119441,0.0004832353,0.0009610031,0.001024077,0.0003783552,0.004132476,0.00132552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008124936,"about_ca_system_score_gemma":0.001159383,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00143264,"about_ca_topic_score_gemma":0.002543647,"domain_scores_codex":[0.9996539,0.0001427323,0.00001600998,0.00006228664,0.00002929859,0.00009581906],"domain_scores_gemma":[0.9996029,0.00005059743,0.00004278149,0.0000327329,0.00001819362,0.0002528774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.782895,0.03990116,0.005807969,0.0005263933,0.001587146,0.0002405771,0.0002633979,0.002323951,0.04732001,0.0004112067,0.004179657,0.1145435],"study_design_scores_gemma":[0.6190246,0.3518056,0.01584754,0.00003750136,0.0008271275,0.0003905055,0.00007847219,0.001554728,0.005597981,0.0001958409,0.004593164,0.00004692228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924012,0.002255205,0.000411471,0.0004317825,0.0001204762,0.0007907128,0.001179255,0.0001674849,0.002242477],"genre_scores_gemma":[0.9886502,0.001804022,0.001146944,0.0007715708,0.0001545405,0.0009901507,0.003381276,0.00005871976,0.003042545],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0044059,"threshold_uncertainty_score":0.01473916,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06491574675293652,"score_gpt":0.4117682651337963,"score_spread":0.3468525183808597,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}